125 related articles for article (PubMed ID: 38697852)
1. Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group.
Rollison HE; Mitra P; Chanteux H; Fang Z; Liang X; Park SH; Costales C; Hanna I; Thakkar N; Vergis JM; Bow DAJ; Hillgren KM; Brumm J; Chu X; Hop CECA; Lai Y; Li CY; Mahar KM; Salphati L; Sane R; Shen H; Taskar K; Taub M; Tohyama K; Xu C; Fenner KS
Drug Metab Dispos; 2024 Jun; 52(7):582-596. PubMed ID: 38697852
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites.
Ellens H; Johnson M; Lawrence SK; Watson C; Chen L; Richards-Peterson LE
Drug Metab Dispos; 2017 Jun; 45(6):646-656. PubMed ID: 28320730
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
[TBL] [Abstract][Full Text] [Related]
4. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
[TBL] [Abstract][Full Text] [Related]
5. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
[TBL] [Abstract][Full Text] [Related]
7. Preincubation Time-Dependent, Long-Lasting Inhibition of Drug Transporters and Impact on the Prediction of Drug-Drug Interactions.
Nozaki Y; Izumi S
Drug Metab Dispos; 2023 Sep; 51(9):1077-1088. PubMed ID: 36854606
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Vermeer LM; Isringhausen CD; Ogilvie BW; Buckley DB
Drug Metab Dispos; 2016 Mar; 44(3):453-9. PubMed ID: 26668209
[TBL] [Abstract][Full Text] [Related]
9. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
12. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
Elsby R; Fox L; Stresser D; Layton M; Butters C; Sharma P; Smith V; Surry D
Eur J Pharm Sci; 2011 May; 43(1-2):41-9. PubMed ID: 21440623
[TBL] [Abstract][Full Text] [Related]
13. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
15. A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters.
Tátrai P; Schweigler P; Poller B; Domange N; de Wilde R; Hanna I; Gáborik Z; Huth F
Drug Metab Dispos; 2019 Jul; 47(7):768-778. PubMed ID: 31068368
[TBL] [Abstract][Full Text] [Related]
16. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of potential transporter-mediated drug interactions of evogliptin.
Lee DY; Chae HW; Shim HJ
Biopharm Drug Dispos; 2017 Sep; 38(6):398-403. PubMed ID: 28503751
[TBL] [Abstract][Full Text] [Related]
18. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
20. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]